An artificial neural network approach integrating plasma proteomics and

1

genetic data identifies PLXNA4 as a new susceptibility locus for 2 3 pulmonary embolism. 4 5 Misbah Razzaq<sup>1,2</sup>, Maria Jesus Iglesias<sup>3,4</sup>, Manal Ibrahim-Kosta<sup>,5,6</sup>, Louisa 6 Goumidi<sup>5,6</sup>, Omar Soukarieh<sup>1,2</sup>, Carole Proust<sup>1,2</sup>, Maguelonne Roux<sup>2</sup>, Pierre 7 Suchon<sup>5,6,</sup> Anne Boland<sup>2,7</sup>, Delphine Daiain<sup>2,7</sup>, Robert Olaso<sup>2,7,</sup> Lynn Butler<sup>3,4,8</sup>, Jean-8 François Deleuze<sup>2,7,9</sup>, Jacob Odeberg<sup>3,4</sup>, Pierre-Emmanuel Morange<sup>,5,6\*</sup>, David-9 Alexandre Trégouët<sup>1,2\*</sup> 10 11 <sup>1</sup> Univ. Bordeaux, INSERM, BPH, U1219, F-33000 Bordeaux, France 12 13 <sup>2</sup> Laboratory of Excellence GENMED (Medical Genomics) 14 <sup>3</sup> Science for Life Laboratory, Department of Protein Science, CBH, KTH Royal Institute of 15 Technology, Stockholm, Sweden. <sup>4</sup> Department of Clinical Medicine, Faculty of Health Science, the Arctic University of 16 17 Tromsö, Norway <sup>5</sup> Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France 18 19 <sup>6</sup> Hematology Laboratory, La Timone University Hospital of Marseille, Marseille, France 20 <sup>7</sup> Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine, 21 91057, Evry, France 22 <sup>8</sup> Clinical Chemistry and Blood Coagulation Research, Department of Molecular Medicine 23 and Surgery, Karolinska Institute, SE-171 76 Stockholm, Sweden 24 <sup>9</sup> Centre d'Etude du Polymorphisme Humain, Fondation Jean Dausset, Paris, France 25 \* These two authors equally contributed to the work. 26 27 28 Corresponding authors: Trégouët David-Alexandre: david-alexandre.tregouet@u-bordeaux.fr; INSERM U1219, 29 30 VINTAGE, case 11, Bordeaux Population Health research center, 146 rue Léo Saignat, 33076 Bordeaux, France. Tel: +33 5 47 30 42 54 31 Razzaq Misbah: misbah.razzaq@inserm.fr; INSERM U219, VINTAGE, case 11, Bordeaux 32 33 Population Health research center, 146 rue Léo Saignat, 33076 Bordeaux, France 34 35

1

#### 36

#### 37 Abstract

- 38 Venous thromboembolism is the third common cardiovascular disease and is composed of 39 two entities, deep vein thrombosis (DVT) and its fatal form, pulmonary embolism (PE).
- two entities, deep vein thrombosis (DVT) and its fatal form, pulmonary embolism (PE).
  While PE is observed in ~40% of patients with documented DVT, there is limited biomarkers
- 41 that can help identifying patients at high PE risk.
- To fill this need, we implemented a two hidden-layers artificial neural networks (ANN) on 376 antibodies and 19 biological traits measured in the plasma of 1388 DVT patients, with or without PE, of the MARTHA study. We used the LIME algorithm to obtain a linear
- 44 without PE, of the MARTHA study. We used the LIME algorithm to obtain a linear 45 approximate of the resulting ANN prediction model. As MARTHA patients were typed for
- 46 genotyping DNA arrays, a genome wide association study (GWAS) was conducted on the
- 47 LIME estimate. Detected single nucleotide polymorphisms (SNPs) were tested for association
- with PE risk in MARTHA. Main findings were replicated in the EOVT study composed of143 PE patients and 196 DVT only patients.
- 50 The derived ANN model for PE achieved an accuracy of 0.89 and 0.79 in our training and 51 testing sets, respectively. A GWAS on the LIME approximate identified a strong statistical
- 52 association peak ( $p = 5.3 \times 10^{-7}$ ) at the *PLXNA4* locus, with lead SNP rs1424597 at which the
- 53 minor A allele was further shown to associate with an increased risk of PE (OR = 1.49 [1.12 1.49]
- 54 1.98],  $p = 6.1 \times 10^{-3}$ ). Further association analysis in EOVT revealed that, in the combined
- 55 MARTHA and EOVT samples, the rs1424597-A allele was associated with increased PE risk 56 (OR =  $1.74 [1.27 - 2.38, p = 5.42 \times 10^{-4})$  in patients over 37 years of age but not in younger
- 57 patients (OR = 0.96 [0.65 1.41], p = 0.848).
- 58 Using an original integrated proteomics and genetics strategy, we identified *PLXNA4* as a new
- 59 susceptibility gene for PE whose exact role now needs to be further elucidated.
- 60

# 61 Author Summary

62 Pulmonary embolism is a severe and potentially fatal condition characterized by the presence 63 of a blood clot (or thrombus) in the pulmonary artery. Pulmonary embolism is often the 64 consequence of the migration of a thrombus from a deep vein to the lung. Together with deep 65 vein thrombosis, pulmonary embolism forms the so-called venous thromboembolism, the third most common cardiovascular disease, and its prevalence strongly increases with age. 66 67 While pulmonary embolism is observed in  $\sim 40\%$  of patients with deep vein thrombosis, there 68 is currenly limited biomarkers that can help predicting which patients with deep vein 69 thrombosis are at risk of pulmonary embolism. We here deployed an Artificial Intelligence 70 based methodology integrating both plasma proteomics and genetics data to identify novel 71 biomarkers for PE. We thus identified the PLXNA4 gene as a novel molecular player involved 72 in the pathophysiology of pulmonary embolism. In particular, using two independent cohorts 73 totalling 1,881 patients with venous thromboembolism among which 467 experienced 74 pulmonary embolism, we identified a genetic polymorphism in the PLXNA4 gene that 75 associates with ~2 fold increased risk of pulmonary embolism in patients aged more than ~40 76 years.

- 77
- 78

79

#### 80

#### 81 Introduction

82 Deep vein thrombosis (DVT) and Pulmonary Embolism (PE) are often considered as two 83 sides of the same coin, venous thromboembolism (VTE), the third most common 84 cardiovascular disease. VTE is a complex disease resulting from the interplay of various 85 factors including (epi-)genetics and environmental sources. VTE incidence is estimated at 1 per 1000 patient-years, and its fatal form, PE, is associated with a mortality rate of 86 87 6% in the acute phase and 20% after one year [1]. PE generally results from the 88 migration of a blood clot from a deep vein to the lung and is observed in  $\sim 40\%$  of 89 patients with documented DVT [2]. However, isolated PE without any trace of DVT can 90 also be observed either when the clot has completely migrated to the lung or when it is a 91 pulmonary clot in situ as recently highlighted in COVID-19 patients [3]. Even though 92 some specific risk factors for PE have been identified in DVT patients such as obesity, 93 sickle cell disease [4] as well as some genetic variations in F5 [4] and GRK5 [5] genes, the 94 exact, likely multifactorial, biological mechanisms that lead to PE are still not fully 95 characterized. Besides, there is still limited biomarkers that can help discriminating 96 patients that will develop PE from those who won't, the former being then at higher risk 97 of death. Thus, there is clearly a need for novel PE-associated molecular markers to be 98 identified.

99 Plasma is an ideal potential source for VTE biomarkers; the intravascular 100 compartment itself is the site of disease manifestation and tests are relatively non-101 invasive, quick and cheap. Several types of molecular determinants can be assessed in 102 plasma samples including microRNAs, metabolites and proteins, and all of them have 103 been investigated in the context of VTE. For example, plasma microRNAs have been 104 assessed in relation to VTE recurrence [6,7]. Plasma proteomics has been employed to 105 discover novel proteins associated with VTE risk [8,9] and plasma metabolomics used to 106 identify novel mechanisms involved in VTE etiology [10,11]. Only one study has so far 107 adopted an exploratory plasma proteomics strategy to identify novel proteins associated 108 with high-risk versus low-risk of PE in humans. This study [12] was based on a relatively 109 small sample size and compared 6 patients with high risk of PE to 6 patients at low PE 110 risk, risk being classified based on clinical presentations and symptoms, with plasma 111 samples profiled by matrix-assisted laser desorption/ionization-time-of-flight/time-of-112 flight mass spectrometry (MALDI-TOF/TOF MS).

113 In this work, we aim at identifying novel molecular phenotypes that could help in 114 better characterizing the biological mechanisms involved in the development of PE in 115 VTE patients. For this, 234 plasma proteins targeted with 376 protein specific 116 antibodies, with the major part derived from the Human Protein Atlas (HPA) repository 117 [13] were profiled in 1388 VTE patients selected from the MARTHA study [14,15] and 118 from whom 283 had experienced a symptomatic PE event. To explore far beyond the 119 search for linear associations between protein levels and PE risk and to identify more 120 complex relationships that could serve as integrative markers of upstream/downstream 121 mechanisms involving molecular determinants that have not necessarily been 122 measured, we deployed a sequential procedure implementing several methodologies 123 selected from the deep-learning domain. Briefly, and as summarized in Figure 1 and 124 more detailled thereafter, the first step consists in applying an under-sampling 125 algorithm (edited nearest neighbors) [16] to remove individuals with strong data 126 heterogeneity that would hamper the efficiency of the downstream analyses, leaving to 127 subsample of 592 VTE patients (497 DVT and 95 PE). This subsample was then used in 128 an Artifical Neural Network (ANN) learning framework in order to predict PE from 129 proteomics data. We then used the Local Interpretable Model-agnostic Explanations 130 (LIME) algorithm [17] to derive a linear approximate of the ANN based predictor for PE 131 risk which would, in addition, have a more meaningful biological interpretation. As 132 MARTHA patients have been previously typed for genome-wide genotype data, we then 133 conducted a genome wide association study of the LIME predictor of PE in order to 134 detect single nucleotide polymorphisms (SNPs) associated with the predictor with the 135 hope that the integration of genetic and proteomic data could provide additional insights 136 into the pathophysiology underlying the identified predictor [18,19]. SNPs with strong statistical association with the LIME predictor were tested for association with PE risk in 137 138 the whole original MARTHA dataset and significant associations were further tested for replication in an independent study of 339 VTE patients including 143 with PE. 139 140 Sequencing data were also scrutinized in some patients with observed VTE outcomes poorly predicted by our ANN/LIME prediction models in order to identify rare variants 141 142 that could be responsible for the observed phenotypes.

143

144 **Figure 1** Analysis workflow of the present study

145

#### 146 **Results**

147 Data description - The MARTHA proteomics substudy was composed of 1,388 VTE 148 patients among which 1,105 were diagnosed for DVT, 95 with isolated PE and 188 with 149 both DVT and PE (Table 1). Patients were phenotyped for 19 quantitative traits known 150 to be involved in thrombotic biological processes (Supplementary Table 1) and for 234 151 different proteins using targeted affinity proteomics with 376 protein specific antibody 152 reagents using multiplexed suspension bead array technology. These proteins were 153 selected for 1) their known roles in the coagulation/fibrinolysis cascade and/or 154 intermediate traits of relevance to thrombosis, 2) their specific expression in endothelial 155 cells (a key cell type involved in thrombosis physiopathology) or 3) encoded by genes identified in pangenomic studies as associated with several cardiovascular disease-156 157 linked biological pathways (e.g platelet function, renal function, inflammation). The list of antibody reagents with their target proteins is given in Supplementary Table 2. 158

159

#### 160 **Table 1 Characteristics of the MARTHA proteomics study**

161

	DVT	PE	DVT+PE
Ν	1105	95	188
Age at sampling	46.67 (14.90)	48.63 (15.26)	51.57 (16.99)
Age at first VTE	40.89 (15.28)	41.64 (15.02)	44.22 (17.56)
Female sex	716 (65%)	78 (82%)	112 (60 %)
Women under oral			
contraceptives at VTE	286 (26%)	35 (37%)	45 (24%)
event			
FV Leiden (rs6025)	255 (23%)	17 (18%)	39 (21%)
heterozygotes			
Anticoagulant therapy at	303 (27%)	29 (31%)	76 (40%)
plasma sampling			
Smokers	209 (19 %)	18 (19 %)	24 (13 %)
BMI	25.14 (4.57)	25.20(4.39)	26.43(4.62)

162 DVT : Deep Vein Thrombosis ; PE : Pulmonary Embolism ; BMI : Body Mass Index

163 Data shown correspond to mean (standard deviation) and count (percentage) for

164 continuous categorical variables, respectively

165

166 Exploration of this dataset using high-dimensional visualization techniques including

167 principal component analysis, t-SNE [20] and UMAP [21] did not reveal any specific

168 stratification in the data nor outliers (Figure 2) but rather illustrates that the three class

169 of patients (DVT, PE, DVT+PE) could not be easily separated.

170

Figure 2 Graphical representation of the HPAs and biological MARTHA data projected
on the first two principal components derived from standard principal components
analysis (a), t-SNE (b) and UMAP (c) techniques.

- 174
- 175

176 Artificial Neural Network for PE - As the accuracy/efficiency of any ANN strongly 177 depend on the quality/homogeneity of the input data, we first applied the edited nearest 178 neighbors algorithm [16] to perform under sampling of the majority class (DVT) and 179 obtain a more homogeneous set of DVT patients, and further discarded the DVT+PE 180 class to avoid adding noise in discriminating between PE and non PE patients. This 181 strategy led to the selection of a subsample (referred thereafter to as the ANN sample 2) 182 of 592 patients (497 DVT and 95 PE) whose proteomics/biological entered the ANN 183 analysis.

184 A two hidden-layers ANN was then built from the ANN dataset with a training set of 185 576 patients (487 DVT and 89 PE) and a testing set of 16 patients (10 DVT and 6 PE). 186 This allocation was chosen so that the number of PE cases used for training was 187 sufficiently large. Because the training set presented with a strong imbalance with 188 respect to the DVT/PE classes with  $\sim$ 5 times more DVT than PE patients, the ANN was 189 trained iteratively as described in the Materials and Methods section. By completion of 190 the iterative algorithm, the final ANN obtained an area under the operative curve (AUC) 191 of 0.89. Of more interest are the performances of the ANN in the testing set. Indeed, our 192 ANN got F1-scores of 0.82 and 0.60 for the DVT and PE classes, respectively, and a global 193 AUC of 0.79 in the testing set.

194 We then used the LIME algorithm to obtain a local linear approximate of the ANN 195 predictions. In the testing set, the LIME prediction achieved an overal AUC of 0.77 196 instead of 0.79 for ANN. For each of the 16 patients in the testing set, we compared the 197 individual predictions of their observed VTE event provided by the ANN and LIME 198 methods (Table 2). In general, ANN and LIME predictions were rather consistent even if 199 the ANN predictions seem to be more accurate in predicting DVT while LIME appears 200 slightly more accurate in predicting PE. The average prediction in correctly classifying 201 DVT patients was 0.872 by ANN compared to 0.748 by LIME. Note that one DVT patient 202 (individual 10) was wrongly predicted to be PE by the ANN predictor, but not by the 203 LIME predictor. Conversely, the average prediction in correctly classifying PE patients

- was 0.498 by ANN compared to 0.578 by LIME. Two PE patients (individuals 11 & 12)
- 205 presented low predictions of being PE, using both ANN and LIME predictors.
- 206

# 207 Table 2 Individual predictions of VT event provided by ANN and LIME in the 16

- 208 patients of the testing set
- 209

Individual	Observed clinical class	ANN prediction for class PE	Local Prediction for class PE
1	DVT	0.04	0.31
2	DVT	0.00	0.18
3	DVT	0.03	0.24
4	DVT	0.02	0.17
5	DVT	0.00	0.23
6	DVT	0.02	0.32
7	DVT	0.00	0.25
8	DVT	0.04	0.22
9	DVT	0.25	0.34
10	DVT	0.88	0.26
11	PE	0.00	0.30
12	PE	0.20	0.31
13	PE	0.98	0.94
14	PE	1.0	1.0
15	PE	0.01	0.15
16	PE	0.80	0.77

210

211 We then assessed the correlation of the LIME predictor with the available biological 212 phenotypes. No strong correlation was observed (Supplementary Table 3). However, the 213 LIME predictor showed marginal positive correlation with fibrinogen ( $\rho = 0.12$ , p = 5.7 x 10<sup>-3</sup>) and factor VIII ( $\rho = 0.16$ , p = 0.013) plasma levels, and marginal negative 214 215 correlation with prothombin time ( $\rho = -0.10$ , p = 0.029) and protein S ( $\rho = -0.10$ , p = -0.10, p = -0216 0.021) plasma levels. To go further into the biological interpretation of the LIME 217 predictor, we sought to identify which proteins contribute the most to the definition of 218 the LIME predictor. Figure 3 display the top 20 most contributing antibodies/proteins. 219 Of note, 5 proteins tended to have substantial more importance than the remaining ones, 220 among which three include proteins that had been selected because their gene 221 expression (COX4I2, VCL, VWF) was found to be specifically enriched in endothelial cells 222 [22]. 223

Figure 3 List of the top 20 antibodies contributing the most to the prediction model forPE

#### 226

227	Genetics of the LIME predictor To get additional information about the biological
228	mechanisms that could underly the linear LIME predictor, we conducted a GWAS on this
229	predictor considered as a quantitative linear trait in a sample of 574 individuals of the
230	ANN subsample with GWAS data. While no SNP reached genome-wide significance, we
231	observed a peak of strong suggestive statistical association on chromosome 7 at the
232	PLXNA4 locus (Supplementary Figure 1 – Supplementary Table 4). The sentinel SNP (p =
233	$5.33 \ x \ 10^{\text{-7}}$ ) was rs1424597 whose minor A allele with frequency of 0.09 was associated
234	with an increase of $+0.169\pm0.034$ in LIME predictor values. In this subsample, the
235	rs1424597-A allele was slightly more frequent in patients with PE than in patients with
236	DVT only (0.15 vs 0.08, p = $4.1 \times 10^{-3}$ ) (Table 3). The association of rs1424597 with PE
237	risk was then assessed in the remaining MARTHA samples (738 DVT and 230 $\ensuremath{\text{PE}}$
238	(DVT+PE or isolated PE) patients) with available GWAS data and that had not been used
239	for building our ANN model. In this subsample, we observed a trend for an higher
240	frequency of the rs1424597-A allele in PE patients compared to non PE patients (0.10 vs $$
241	0.08), even if the association did not reach significance (p = $0.20$ ).

242

#### 243 Table 3 Association of rs1424597 with PE risk in the MARTHA and EOVT studies

	MARTHA					
	Participants in	ncluded in the	Participants	outside the	EOVT	
	ANN at	nalysis	ANN a	nalysis		
	DVT	PE	DVT	PE	DVT	PE
	N = 480	N = 94	N=738	N=230	N=196	N=143
GG	404 (84%)	71 (75%)	624 (85%)	187 (79%)	149 (76%)	110 (77%)
GA	74 (15%)	18 (19%)	111 (14%)	41 (20%)	47 (24%)	28 (20%)
AA	2 (<1%)	5 (5%)	3 (<1%)	2 (~1%)	0 (-)	5 (3%)
MAF <sup>1</sup>	0.081	0.149	0.079	0.098	0.119	0.133
OR <sup>2</sup>	1.98 [1.24 - 3.14]		1.26 [0.88 – 1.81]		1.12 [0.7	1 - 1.78]
	p = 0.0041		p = 0.204		p = 0.613	

244 MAF : Minor Allele Frequency

245 OR : Allelic Odds Ratio [95%CI] and p-value of the Cochran-Armitage trend test for

- 246 association
- 247

We further investigated the association of rs1424597 with PE in the EOVT study composed of 143 PE patients 196 DVT patient. In EOVT, the rs1424597-A allele frequency was similar between EOVT patients with PE and with DVT (0.13 vs 0.12, p = 0.61) (Table 3). Because by design the EOVT study is enriched with early onset VTE patients, we assessed whether the discrepancy between MARTHA and EOVT results

253	could be due to patient selection criteria (i.e according to age.) We thus split the EOVT
254	samples according to the median of age of VTE onset, that was 37yrs. As shown in Table
255	4, the pattern of association of rs1424597 with PE slightly differed according to age. In
256	EOVT patients younger than 37yrs, its allele frequency tend to be slighty lower in PE
257	than in DVT patients (0.11s 0.13) while the inverse was observed in patients aged more
258	than 37 yrs (0.15 vs0.11). Interestingly, the same observations hold in MARTHA when
259	patients were stratified according to the same age threshold (Table 4). In the combined
260	MARTHA and EOVT samples, the rs1424597-A allele was associated with an increased
261	odds ratio (OR) for PE of 1.74 [1.27 – 2.38] (p = 5.42 x $10^{-4}$ ) in patients over 37 years of
262	age while no association (OR = $0.96 [0.65 - 1.41]$ , p = $0.848$ ) was observed in younger
263	patients. Similar ORs were obtained, OR = 1.73 [1.22 – 2.45] (p = 1.99 x $10^{-3}$ ) and OR =
264	1.08 $[0.77 - 1.53]$ (p = 0.628), respectively, if a more standard age threshold of 40 yrs
265	[23] had been used.

266

# Table 4 Association of rs1424597 with PE risk according to age of onset of venous thrombosis

		Age of onset <37				Age of onset ≥37			
	MA	RTHA	EOVT		MARTHA		EOVT		
	DVT	DVT+PE/PE	DVT	PE	DVT	DVT+PE/PE	DVT	PE	
	N=550	N =147	N=96	N=64	N=668	N =177	N=100	N=79	
GG	464	123	70	51	564	135	79	59	
GA	83	23	26	12	102	36	21	16	
AA	3	1	0	1	2	6	0	4	
MAF <sup>1</sup>	0.081	0.085	0.135	0.109	0.079	0.136	0.105	0.152	
OR <sup>2</sup>	1.056 [0.664 - 1.678]		0.784 [0.392 - 1.566]		1.820 [1.266 - 2.617]		1.53 [0.82 - 2.86]		
	p = 0.817		p = 0.470		p = 1.16 10 <sup>-3</sup>		p = 0.196		

269 MAF : Minor Allele Frequency

270 OR : Allelic Odds Ratio [95%CI] and p-value of the Cochran-Armitage trend test for

- 271 association
- 272
- 273
- 274 Genetics of inconsistent LIME predictions
- As shown in Table 2, our ANN/LIME models failed to correctly predict the true VTE outcome in four individuals from the testing set (individuals 10, 11, 12 and 15). First, it is worthy of note that these 4 individuals were all females. Second, the 3 female PE patients wrongly predicted to be DVT (individuals 11, 12 and 15) were all under oral contraceptives (OC) at the time of the PE event (age 45, 35 and 53, respectively), but not individual 10 incorrectly predicted to be PE. While we cannot rule out the possibility

281 that our ANN/LIME models poorly behave in women under OC, we nevertheless sought 282 to investigate whether discordant predictions could be due to genomic outlier 283 individuals harboring very rare disease causing mutations that could make the global 284 ANN/LIME predictions inaccurate, inline with the idea that the discrepancy between 285 (deep learning derived) predicted and observed phenotypes could be a heritable trait 286 [24]. Among these 4 individuals, only two (Individuals 11 and 15) have been sequenced 287 for their whole genome. Sequence data of these two individuals were then scrutinized 288 for candidate rare variants that could explain the VTE phenotype.

Individual 11 is a woman that experienced PE under oral contraceptives (OC) at age 45. Of note, her ten closest neighbors inferred from HPA data were all DVT patients which would likely explain why the derived ANN predicted her a DVT outcome instead of PE. She was not found to harbour any candidate variation in known VTE genes but presented in her genome with 61 very rare coding variants with strong predicted deleteriousness that could be good candidates responsible for the PE event.

295 Individual 15 is a woman that had experienced PE at age 53 also under OC. Nine out 296 of 10 of her closest proteomics based neighbors were DVT patients which may also 297 explain why this PE patient was uncorrectly predicted to be DVT. This patient was found 298 carry а nonsynonymous variation (rs121918154; to very rare 299 PROC:NM 000312:exon9:c.C814T:p.R272C) in the VTE-associated PROC gene. This 300 variation has a minor allele frequency of 0.005% in public database 301 (https://www.ncbi.nlm.nih.gov/snp/rs121918154), is predicted to be deleterious by 302 several bioinformatic tools and have been previously reported in VTE patients with 303 protein C deficiency [25,26]. This variation is located in the last exon of the gene and is 304 predicted to alter splicing regulatory elements [27–29], which could lead to a deletion of a part of the peptidase S1 domain that is responsible for the clivage activity of the 305 306 protein. Of note, this patient exhibited moderately low plasma Protein C levels, 63%, 307 slightly lower than the 65% threshold adopted to declare moderate protein C deficiency 308 [30].

309

#### 310 **Discussion**

This work is original in at least three main aspects. First, it is the largest plasma proteomic study with respect to pulmonary embolism in VTE patients. Second, it is to our knowledge the first attempt to deploy ANN methodologies on proteomic data with

314 the aim at identifying new molecular thrombotic players. And finally, the integration of

315 proteomic and genomics data identified *PLXNA4* as a new candidate gene for PE.

316 This work started with the implementation of an ANN methodology on antibody based 317 affinity proteomics data in relation to PE risk. This ANN was not developped as a tool to 318 be used in clinic for predicting PE risk as 1/one is not 100% certain about the identity of 319 the identified tagged proteins [31] (further experimental validation would be needed to 320 assess this) and 2/ plasma protein levels determined with the antibody suspension bead 321 array are not absolute but relative values depending on the current set of studied 322 antibodies. Rather, our ANN based predictor for PE was aimed at serving as an 323 intermediate surrogate biomarker that could generate new knowledge about the 324 (genetics) mechanisms involved in PE. By conducting a GWAS on the derived PE 325 predictor and capitalizing on two case-control samples totalling 467 patients with PE 326 and 1414 patients with DVT, we observed that the PLXNA4 rs1424597-A allele was 327 associated with a  $\sim$ 2-fold increased risk of PE in VTE patients aged more than  $\sim$ 40yrs. 328 PLXNA4 codes for Plexin A4, which is part of a receptor complex involved in signal 329 transduction of sempahorin 3A signals linked to cytoskeletal rearrangement, inhibiting 330 integrin adhesion [32,33]. It has a role in axone guidance in nervous system 331 development, and genetic variants in PLXN4 have been linked to risk of Alzhemier 332 disease [34,35]. Based on RNA seq data from HPA, FANTOM and GTEx datasets, PLXNA4 333 is expressed at medium/high levels in central nervous system, adipose, breast and 334 female reproductive tract tissues, and low levels in a broad range of other tissues 335 (https://www.proteinatlas.org/ENSG00000221866-PLXNA4/tissue), indicating roles outside 336 the nervous system. RNA seq data from blood cell populations show expression in 337 plasma cytoid dendritic cells, NK cells and some T-cell populations, and research based 338 on animal studies suggest a role in immunity and immune function. It has been shown to 339 be a negative regulator of T cell activation [36]. Besides, Wen et al [37] found it to be 340 highly expressed in myeloid cells, where PLXNA4 had an important function in 341 stimulating TNF-alpha and IL-6 production in macrophages, where knock out mice were 342 protected against letal dose LPS induced cytokine storms, suggesting it having a critical 343 role in mediating pro-inflammatory cytokine production. The ligand of PLXNA4, SEMA3, 344 has also been described with a role in endothelial cell function in an autocrine loop, 345 promoting processes involved in vascular remodeling [38], and also in negatively 346 regulating platelet aggregation [39]. While PLXNA4 thus has been described with a role

347 in processes/pathways of relevance for thrombosis, little is known about *PLXNA4* in 348 pulmonary embolism. In addition, we did not identify strong elements supporting a 349 functional role of the intronic rs1424597 polymorphisms or of any other 350 polymorphisms in strong linkage disequilibrium with it. Nevertheless, rs1424597 has 351 recently been observed in the FinnGen study (<u>http://r3.finngen.fi/</u>) to be marginaly 352 associated ( $p = 4.5 \ 10^{-3}$ ) with pleural conditions that are inflammatory disorders of the 353 lung. Consistent with this observation, we observed a positive correlation between the 354 rs1424597-associated PE predictor and fibrinogen, a well known inflammatory marker. 355 Additional *PLXNA4* polymorphisms have also been reported to demonstrate strong 356 statistical evidence for association with various lung function markers [40,41]. Besides, 357 our group have previously suggested that *PLXNA4* polymorphisms could interact with 358 polymorphisms at UQCC1 to modulate the risk of VTE in the general population [42], 359 UQCC1 being a locus that have also be shown to be involved in lung function [43]. 360 Altogether, these observations strongly support for a role of *PLXNA4* in lung function 361 and its precise role in the etiology of pulmonary embolism deserve further investigation. 362 Which polymorphisms could be truly responsible for the observed association with PE 363 risk also merits further works as the rs1424597 is likely tagging for functional 364 variant(s)/haplotypes yet to be characterized. Finally, further studies would be needed 365 to investigate whether the previously suggested *PLXNA4* x *UQCC1* interaction on the risk 366 of VTE (combining both DVT and PE) could be more specific to patients with PE.

367 In addition to searching for common polymorphisms that could associate with our ANN 368 based predictor and with PE risk, we also looked for rare variants that could explain the 369 discrepancy between predicted and observed VTE outcome in our testing set. Two out of 370 four patients with discordant predictions in the testing set have been sequenced for 371 their whole genome. Both were females patients that experienced PE under OC. In one of 372 them, we were able to identify a rare VTE causing mutation in *PROC*. It is not our 373 intention to conclude to any general rule about the relevance of searching of rare 374 variants responsible for any discordancy between ANN predictions and observed 375 outcomes. Especially as we observed that the three PE patients wrongly predicted to be DVT were women who developed PE under OC. These observations could suggest that 376 377 our plasma proteomics ANN derived predictions may not be valid in such subgroups of 378 VTE patients and highlight the challenge to identify general prediction models for 379 complex diseases. Several additional limitations must be addressed. First, no plasma

380 antibody targeting PLXNA4 was available when the screening phase of this work was 381 initiated preventing us from validating further its association with PE. Second, no 382 proteomic data was available in the EOVT study to formally replicate the association of 383 our ANN and LIME predictors with PE risk. Third, our GWAS analysis on the ANN 384 derived predictor was performed only in 574 samples which has likely hampered our 385 power to identify genome-wide significant SNPs. We may have then missed additional 386 polymorphisms that could be truly associated with the predictor and could have then 387 help us to better dissentangle its underlying molecular biology. Finally, the moderate 388 sample size of the EOVT study has also likely hampered our power for statistically 389 replicating the association of the lead PLXNA4 polymorphism with PE. In addition, no 390 information was available in the EOVT study to distinguish isolated PE From DVT+PE 391 which prevented us from further testing whether the association of *PLXNA4* with PE risk 392 was mainly restricted to isolated PE as suggested from the MARTHA results. However, 393 the very consistent pattern of association observed according to age strata between the 394 two studies is a strong argument in favor of *PLXNA4* as a new candidate in PE biology.

395 In conclusion, by implementing an original artificial neural network methodology 396 integrating plasma proteomics and genetic data, we identified *PLXNA4* as a new 397 candidate susceptibility gene for PE in VTE patients whose precise role in PE etiology 398 deserve further investigations

399

#### 400 Materials and Methods

401

#### 402 <u>Ethical approval</u>

Each individual study on which the work is based was approved by its institutional
ethics committee and informed written consent was obtained in accordance with the
Declaration of Helsinki. Ethics approval were obtained from the "Departement santé de
la direction générale de la recherche et de l'innovation du ministère" (Projects DC: 2008880 & 09.576) and from the institutional ethics committees of the Kremlin-Bicetre
Hospital.

409

#### 410 <u>MARTHA study</u>

411 The MARTHA population is composed of VTE patients recruited from the Thrombophilia412 center of La Timone hospital (Marseille, France) and free of any chronic conditions and

of any well characterized genetic risk factors including antithrombin, protein C or
protein S deficiency, homozygosity for FV Leiden or Factor II 20210A, and lupus
anticoagulant. Detailed description of the MARTHA population has been provided
elsewhere [14,44].

417 *MARTHA proteomics substudy.* A sample of 1,388 MARTHA patients with available
418 plasma samples were profiled for targeted plasma proteomic investigations as described
419 below.

420 MARTHA genetic substudy. From the whole MARTHA population, 1592 patients
421 with DNA available were genotyped with high-throughput genotyping arrays (see
422 below).

423

424 <u>Plasma proteomic profiling</u>

425 Generation of antibody suspension bead array (SBA)

426 The multiplex antibody suspension bead array (SBA) was created by covalent coupling 427 of 339 Human Protein Atlas (HPA) antibodies, 13 from commercial providers and 25 428 monoclonal BSI antibodies (BioSystems International Kft) targeting 234 unique 429 candidate proteins (Supplemental Table 2). Antibodies were individually coupled to 430 carboxylated magnetic beads (MagPlex-C, Luminex Corp.) generating up to 384 different 431 bead identities (IDs), essentially according to methods previously described [45,46]. The 432 final multiplexed suspension bead array was prepared by combining all 384 antibody 433 coupled beads into a single SBA stock with a concentration of approximately 25-40 434 beads of each antibody bead ID/ul.

435

#### 436 Plasma labelling and protein profiling assay

437 Plasma samples were diluted 1:10 in filtered 1xPBS and labelled with biotin (NHS-PEG4-438 Biotin, Thermo Scientific) for 2h at 4°C. The labelling process was terminated by the 439 addition of 12.5ul of 0.5M HCl pH:8.0 to each sample for 20 min and consecutively 440 storage at -20°C until usage [45]. Labelled plasma samples were diluted 1:50 in PVX casein buffer + 10% (v/v) rabbit IgG (0.1% casein, 0.5% polyvinyl alcohol, 0.8% 441 442 polyvinylpyrrolidone, prepared in 1xPBS). Diluted samples were heat-induced to 443 achieve epitope retrieval for 30 minutes at 56°C. Five microliters of the SBA were mixed 444 with 45ul of heat-treated samples for 16-18 hours, at RT and constant shake. Unbound 445 complexes were removed by 2 consecutive washes with PBS-T and antibody-bound

446 complexes were cross-linked by resuspending the beads in 0.4% PFA-PBS for 10 min. R-447 phycoerythrin-conjugated streptavidin (1:750, PBS-T; Invitrogen) was added to all 448 samples for 30 min followed by 2 times washes. Relative amount of each protein 449 complex was expressed as median of fluorescence intensity (MFI) by read out on a 450 FlexMAP3D.

451

452 <u>The Early Onset Venous Thrombosis (EOVT) study</u>

This study is composed of 339 VTE patients with documented idiopathic isolated PE or DVT selected according to the same criteria as the MARTHA participants, with the exception that the age of VTE onset was below 50 yrs. Detailed description can be found in [44,47]

457

458 <u>Deep-learning framework for identifying a molecular predictor of PE risk.</u>

459 Step 1 : Normalization

460 First, all HPA variables were normalized and scaled to have 0 mean et 1 variance to
461 avoid major artificial influence of variables with large range of variations.

462

463 Step2 : Edited nearest neighbors

464 As our aim was to identify new molecular markers associated with PE, we 465 hypothesized that conducting our discovery phase on isolated PE, an expected less 466 heterogeneous class of VTE patients than the class of patients with both DVT and PE, will 467 increase our chance to identify novel relevant molecular players. As a consequence, we 468 decided to built our ANN model only on patients with isolated PE (N = 95) or with DVT 469 (N = 1105). However, due to the imbalance nature of this dataset with ~10 more samples in the DVT class than in the PE class, we applied the edited nearest neighbors 470 471 (ENN) algorithm, an under sampling method usually used in the field of pattern 472 recognition or classification in presence of unbalanced samples [16]. This method relies 473 on under sampling unit of analysis, in our case individuals, from the majority class by 474 removing the most heteregenous units. It consists in computing the Euclidian distance 475 between each pair of individuals from their proteomics data and to remove samples 476 whose clinical phenotype (here DVT) is not consistent with that of his/her k nearest 477 neighbors (k=3 in this work). This led us to the selection of the so called ANN dataset 478 composed of N = 497 DVT and N = 95 PE patients for building our ANN model.

480 Step3: Derivation of an ANN model for PE prediction.

To build our ANN model, the ANN dataset was divided into a training set composed of 576 patients (487 DVT and 89 PE) and a testing set of 16 patients (10 DVT and 6 PE), the latter being used for testing the accuracy of the ANN model derived from the former. This allocation was chosen so that the number of PE cases used for training was sufficiently large.

Because the application of a standard ANN methodology to our training set would
lead to instable network for predicting PE due to the imbalance nature of the input data
with ~5 times more DVT than PE patients, an interative ANN framework was adopted:

489 At each iteration *i*,

A random sample of 30 PE patients and 100 DVT patients is selected from the
training set and a sample of 70 synthetic PE samples are generated using the ADASYN
algorithm [48]. ADASYN is an adaptive synthetic data generation method where new
samples are generated based on the weighted distribution for minority class samples
with two main advantages, resolving data imbalance and forcing classifiers to be more
sensitive to the minority class. This strategy led to a balanced dataset D*i* of 100 PE and
100 DVT (synthetic) patients on which a ANN is built.

497 - Using the Di dataset further splitted randomly into 90%/10% training/testing 498 subsamples, a two hidden-layers feed forward neural networks was implemented. The 499 first hidden layer has 395 neurons corresponding to the number of input (proteomic & 500 biological) variables, the second layer 128 while the output layer consisted in 2 neurons, 501 representing the DVT and PE classes respectively. The number of neurons were selected 502 by trial and error approach under the constraint that the number of neurons shall be 503 smaller than the number of input variables and higher than the number of output classes 504 The Rectified Linear Unit (ReLU) function [49]was used to activate hidden layers 505 while the softmax activation function [50] was used to generate class probabilities in the 506 output layer.

After fixing the number of nodes, layer and activation function, the process of training the neural network can start. Starting from random weights, forward propagation is used to generate the output of all nodes at all layers while moving from the input to the output layers. The generated final output is compared to the observed class phenotype and an error is calculated using the cross-entropy function [51]. Iteratively, this error

512 was then backpropagated using a gradient descent algorithm [52] (with learning of 0.01 513 and batch size of 32) to update weights according to their contribution to the error. In 514 order to reduce over-fitting and obtain the best performing model, the callback feature 515 proposed by the Keras open-source library (https://keras.io/) that was employed for 516 developping this ANN framework was used.

517

## 518 Step4: Local Interpretable Model-Agnostic Explanations (LIME)

As a neural network is often considered as a black box without telling much about which, and how, input variables contribute the most to the predictive model, the LIME methodology [17] was applied to the final ANN model obtained at Step 3 in order to inform about which input variables (i.e plasma proteoin levels) contribute top PE risk prediction and what are the relative weights using a linear approximation of the ANN model.

525

### 526 Genome Wide Genotyping

As previously described [15,44], both MARTHA and EOVT participants have been genotyped with high-density genotyping Illumina arrays and imputed for single nucleotide polymorphisms (SNPs) from the 1000G Phase I Integrated Release Version 2 Haplotypes using MACH (v1.0.18.c) and Minimac (release 2011-10-27) imputation software.

532

#### 533 <u>Genome-Wide Association analysis (GWAS)</u>

534 Imputed SNPs with imputation quality  $r^2$  greater than 0.5 and with minor allele 535 frequency (MAF) greater than 0.01. were tested for association with the LIME predictor 536 derived in 574 MARTHA participants. Associations with statistical p-value < 5 x 10<sup>-8</sup> 537 were considered as genome-wide significant.

538

#### 539 Genetic Association Analysis with PE risk

The candidate SNP identified from the GWAS on the LIME predictor was tested for its association with PE risk, both in MARTHA and EOVT participants. For this, we employed the Cochran-Armitage trend for association applied to the best guessed genotypes inferred from the imputed allele dosage at the SNP of interest. Meta-analysis of the association results observed in MARTHA and EOVT was conducted using a fixed-effects

model based on the inverse-variance weighting and heterogeneity of association
between the two studies was assessed by the Cochran-Mantel-Haenszel test statisticsn-

- 547 Mantel-Haenszel test statistic [53]
- 548

#### 549 <u>Whole Genome Sequencing</u>

550 From the whole MARTHA study, 200 patients had been selected for whole genome 551 sequencing. These patients were selected to have experienced unprovoked VTE. Besides, 552 these patients should have family history of VTE or multiple unprovoked VTE events, such 553 clinical patterns being compatible with the existence of an underlying VTE causing genetic 554 defect. Genomic DNA was extracted from peripheral blood, using the BioRobot EZ1 555 workstation. The DNA concentration was determined using the Qubit assay kit 556 (Thermofisher). Whole genome sequencing was performed at the Centre National de 557 Recherche en Génomique Humaine (CNRGH, Institut de Biologie François Jacob, Evry, 558 FRANCE). After a complete quality control, 1µg of genomic DNA was used for each sample 559 to prepare a library for whole genome sequencing, using the Illumina TruSeq DNA PCR-Free 560 Library Preparation Kit, according to the manufacturer's instructions. After normalisation and 561 quality control, qualified libraries were sequenced on a HiSeqX5 instrument from Illumina 562 (Illumina Inc., CA, USA) using a paired-end 150 bp reads strategy. One lane of HiSeqX5 563 flow cell was used per sample specific library in order to reach an average sequencing depth 564 of 30x for each sequenced individual. Sequence quality parameters have been assessed 565 throughout the sequencing run and standard bioinformatics analysis of sequencing data was 566 based on the Illumina pipeline to generate FASTQ file for each sample. FastQ sequences were 567 aligned on human genome hg37 using the BWA-mem program [54]. Variant calling was 568 GATK HaplotypeCaller performed using the (GenomeAnalysisTK-v3.3-0, 569 https://software.broadinstitute.org/gatk/documentation/article.php?id=4148). Single-sample 570 gVCFs files were then aggregated using GATK CombineGVCFs and joint genotyping calling 571 performed by GATK GenotypeGVCFs. Recalibration was then conducted on the whole gVCF 572 following GATK guidelines. Following GATK VQSR, we retained single nucleotide variants 573 in the 99.5% tranche sensitivity threshold and indels in the 99% tranche sensitivity threshold 574 for further analysis and annotated them using Annovar [55].

As a strategy to identify candidate variants that could explain the VTE phenotype in individuals with discordant class prediction, we first prioritized variants that were likely functional (stop loss/stop gain, frameshift, non-synonymous and splicing variants), located in known VTE associated genes (ABO, ARID4A, C4BPB, EIF5A, F2, F3, F5, F8, F9, F13A1,

579 FGG, GRK5, MPHOSPH9, MAST2, NUGCC, OSMR, PLAT, PLCG2, PLEK1, PROC, 580 PROS1, SCARA5, SERPINC1, SLC44A2, STAB2, STX10, STXBP5, THBD, TSPAN15, 581 VWF) [56–58], that have not been reported or at a low frequency ( $<1\infty$ ) in public genomic 582 data repositories (dbSNP, GnomAD) and that was present in only one of the 200 sequenced 583 patients. If no candidate variants was identified in known VTE genes, we extended our search 584 to whole coding genes and also took into account the predicted deleteriousness of selected 585 candidates using *in silico* tools such as SIFT, PolyPhen and CADD-v1.2 [59] to further reduce 586 the number of candidates.

- 587
- 588

#### 589 Acknowledgments

590 Mi.R; O.S. and Ma.R and the production of the MARTHA genomics data were financially 591 supported by the GENMED Laboratory of Excellence on Medical Genomics [ANR-10-592 LABX-0013], a research program managed by the National Research Agency (ANR) as part 593 of the French Investment for the Future. This work benefited from the financial support from 594 the «EPIDEMIOM-VTE» Senior Chair from the Initiative of Excellence of the University of 595 Bordeaux. Bioinformatics and statistical analyses benefit from the CBiB computing centre of 596 the University of Bordeaux. The proteomics screening was financed by a grant from 597 Stockholm Councy Council (SLL 2017-0842) and from Familjen Erling Perssons Foundation.

598

#### 599 **References**

- White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107: I4-8.
   doi:10.1161/01.CIR.0000078468.11849.66
- Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, et al.
   2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.
   Eur Heart J. 2014;35: 3033–3069, 3069a–3069k. doi:10.1093/eurheartj/ehu283
- 605 3. Contou D, Pajot O, Cally R, Logre E, Fraissé M, Mentec H, et al. Pulmonary embolism
  606 or thrombosis in ARDS COVID-19 patients: A French monocenter retrospective study.
  607 PLoS One. 15: e0238413.
- 4. van Langevelde K, Flinterman LE, van Hylckama Vlieg A, Rosendaal FR, Cannegieter
  SC. Broadening the factor V Leiden paradox: pulmonary embolism and deep-vein
  thrombosis as 2 sides of the spectrum. Blood. 2012;120: 933–946. doi:10.1182/blood2012-02-407551

612 613 614 615	5.	Rodriguez BAT, Bhan A, Beswick A, Elwood PC, Niiranen TJ, Salomaa V, et al. A Platelet Function Modulator of Thrombin Activation Is Causally Linked to Cardiovascular Disease and Affects PAR4 Receptor Signaling. Am J Hum Genet. 2020. doi:10.1016/j.ajhg.2020.06.008
616 617 618	6.	Wang X, Sundquist K, Svensson PJ, Rastkhani H, Palmér K, Memon AA, et al. Association of recurrent venous thromboembolism and circulating microRNAs. Clin Epigenetics. 2019;11: 28. doi:10.1186/s13148-019-0627-z
619 620 621 622	7.	Thibord F, Munsch G, Perret C, Suchon P, Roux M, Ibrahim-Kosta M, et al. Bayesian network analysis of plasma microRNA sequencing data in patients with venous thrombosis. Eur Heart J Suppl. 2019. Available: https://www.hal.inserm.fr/inserm-02310241
623 624 625 626	8.	Bruzelius M, Iglesias MJ, Hong M-G, Sanchez-Rivera L, Gyorgy B, Souto JC, et al. PDGFB, a new candidate plasma biomarker for venous thromboembolism: results from the VEREMA affinity proteomics study. Blood. 2016;128: e59–e66. doi:10.1182/blood-2016-05-711846
627 628 629 630	9.	Jensen SB, Hindberg K, Solomon T, Smith EN, Lapek JD, Gonzalez DJ, et al. Discovery of novel plasma biomarkers for future incident venous thromboembolism by untargeted synchronous precursor selection mass spectrometry proteomics. J Thromb Haemost. 2018;16: 1763–1774. doi:10.1111/jth.14220
631 632 633 634 635	10.	Fraser K, Roy N, Goumidi, Louisa, Verdu A, Suchon P, Leal-Valentim F, et al. Plasma Biomarkers and Identification of Resilient Metabolic Disruptions in Patients With Venous Thromboembolism Using a Metabolic Systems Approach. In: Arteriosclerosis, thrombosis, and vascular biology [Internet]. Arterioscler Thromb Vasc Biol; 8 Jun 2020 [cited 16 Sep 2020]. doi:10.1161/ATVBAHA.120.314480
636 637 638 639	11.	Zeleznik OA, Poole EM, Lindstrom S, Kraft P, Van Hylckama Vlieg A, Lasky-Su JA, et al. Metabolomic analysis of 92 pulmonary embolism patients from a nested case-control study identifies metabolites associated with adverse clinical outcomes. J Thromb Haemost. 2018;16: 500–507. doi:10.1111/jth.13937
640 641 642 643	12.	Insenser M, Montes-Nieto R, Martínez-García MÁ, Durán EF, Santiuste C, Gómez V, et al. Identification of reduced circulating haptoglobin concentration as a biomarker of the severity of pulmonary embolism: a nontargeted proteomic study. PLoS ONE. 2014;9: e100902. doi:10.1371/journal.pone.0100902
644 645 646	13.	Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347: 1260419. doi:10.1126/science.1260419
647 648 649 650	14.	Oudot-Mellakh T, Cohen W, Germain M, Saut N, Kallel C, Zelenika D, et al. Genome wide association study for plasma levels of natural anticoagulant inhibitors and protein C anticoagulant pathway: the MARTHA project. Br J Haematol. 2012;157: 230–239. doi:10.1111/j.1365-2141.2011.09025.x

651	15.	Germain M, Chasman DI, de Haan H, Tang W, Lindström S, Weng L-C, et al. Meta-
652		analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility
653		loci for venous thromboembolism. Am J Hum Genet. 2015;96: 532–542.
654		doi:10.1016/j.ajhg.2015.01.019

- Wilson D L. Asymptotic properties of nearest neighbor rules using edited data. IEEE
   Transactions on Systems, Man, and Cybernetics. 1972;3: 408–421.
- Ribeiro MT, Singh S, Guestrin C. Why should i trust you?" explaining the predictions of
  any classifier. Proceedings of the 22nd ACM SIGKDD International Conference on
  Knowledge Discovery and Data Mining. 2016; 1135–1144.
- Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, et al. Genomic
  atlas of the human plasma proteome. Nature. 2018;558: 73–79. doi:10.1038/s41586-0180175-2
- Suhre K, Arnold M, Bhagwat AM, Cotton RJ, Engelke R, Raffler J, et al. Connecting
  genetic risk to disease end points through the human blood plasma proteome. Nat
  Commun. 2017;8: 14357. doi:10.1038/ncomms14357
- Maaten L, Hinton G. Visualizing data using t-SNE. ournal of machine learning research.
  2008;9: 2579–2605.
- McInnes L, Healy J. UMAP: Uniform manifold approximation and projection for
   dimension reduction. arXiv preprint arXiv:180203426. 2018.
- Butler LM, Hallström BM, Fagerberg L, Pontén F, Uhlén M, Renné T, et al. Analysis of
  Body-wide Unfractionated Tissue Data to Identify a Core Human Endothelial
  Transcriptome. Cell Syst. 2016;3: 287-301.e3. doi:10.1016/j.cels.2016.08.001
- Anderson FA, Spencer FA. Risk factors for venous thromboembolism. Circulation.
  2003;107: I9-16. doi:10.1161/01.CIR.0000078469.07362.E6
- 4. Jonsson BA, Bjornsdottir G, Thorgeirsson TE, Ellingsen LM, Walters GB, Gudbjartsson
  DF, et al. Brain age prediction using deep learning uncovers associated sequence
  variants. Nature Communications. 2019;10: 5409. doi:10.1038/s41467-019-13163-9
- Allaart CF, Poort SR, Rosendaal FR, Reitsma PH, Bertina RM, Briët E. Increased risk of
  venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet.
  1993;341: 134–138. doi:10.1016/0140-6736(93)90003-y
- Reitsma PH, Poort SR, Allaart CF, Briët E, Bertina RM. The spectrum of genetic defects
  in a panel of 40 Dutch families with symptomatic protein C deficiency type I:
  heterogeneity and founder effects. Blood. 1991;78: 890–894.
- Erkelenz S, Theiss S, Otte M, Widera M, Peter JO, Schaal H. Genomic HEXploring
  allows landscaping of novel potential splicing regulatory elements. Nucleic Acids Res.
  2014;42: 10681–10697. doi:10.1093/nar/gku736

687 688 689	28.	Ke S, Shang S, Kalachikov SM, Morozova I, Yu L, Russo JJ, et al. Quantitative evaluation of all hexamers as exonic splicing elements. In: Genome research [Internet]. Genome Res; Aug 2011 [cited 21 Sep 2020]. doi:10.1101/gr.119628.110
690 691 692	29.	Tubeuf H, Charbonnier C, Soukarieh O, Blavier A, Lefebvre A, Dauchel H, et al. Large- scale comparative evaluation of user-friendly tools for predicting variant-induced alterations of splicing regulatory elements. Hum Mutat. 2020. doi:10.1002/humu.24091
693 694 695 696 697	30.	Lijfering WM, Brouwer J-L P, Veeger, Nic J. G. M., Bank I, Coppens M, Middeldorp, Saskia, et al. Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. In: Blood [Internet]. Blood; 21 May 2009 [cited 16 Sep 2020]. doi:10.1182/blood-2008-10-184879
698 699 700	31.	Fredolini C, Byström S, Sanchez-Rivera L, Ioannou M, Tamburro D, Pontén F, et al. Systematic assessment of antibody selectivity in plasma based on a resource of enrichment profiles. Sci Rep. 2019;9: 8324. doi:10.1038/s41598-019-43552-5
701 702	32.	Hu S, Zhu L. Semaphorins and Their Receptors: From Axonal Guidance to Atherosclerosis. Front Physiol. 2018;9: 1236. doi:10.3389/fphys.2018.01236
703 704	33.	Fard D, Tamagnone L. Semaphorins in health and disease. Cytokine Growth Factor Rev. 2020. doi:10.1016/j.cytogfr.2020.05.006
705 706 707	34.	Han Q, Sun Y-A, Zong Y, Chen C, Wang H-F, Tan L, et al. Common Variants in PLXNA4 and Correlation to CSF-related Phenotypes in Alzheimer's Disease. Front Neurosci. 2018;12: 946. doi:10.3389/fnins.2018.00946
708 709 710	35.	Jun G, Asai H, Zeldich E, Drapeau E, Chen C, Chung J, et al. PLXNA4 is associated with Alzheimer disease and modulates tau phosphorylation. Ann Neurol. 2014;76: 379–392. doi:10.1002/ana.24219
711 712 713	36.	Yamamoto M, Suzuki K, Okuno T, Ogata T, Takegahara N, Takamatsu H, et al. Plexin- A4 negatively regulates T lymphocyte responses. Int Immunol. 2008;20: 413–420. doi:10.1093/intimm/dxn006
714 715 716	37.	Wen H, Lei Y, Eun S-Y, Ting JP-Y. Plexin-A4-semaphorin 3A signaling is required for Toll-like receptor- and sepsis-induced cytokine storm. J Exp Med. 2010;207: 2943–2957. doi:10.1084/jem.20101138
717 718	38.	Bussolino F, Valdembri D, Caccavari F, Serini G. Semaphoring vascular morphogenesis. Endothelium. 2006;13: 81–91. doi:10.1080/10623320600698003
719 720 721	39.	Kashiwagi H, Shiraga M, Kato H, Kamae T, Yamamoto N, Tadokoro S, et al. Negative regulation of platelet function by a secreted cell repulsive protein, semaphorin 3A. Blood. 2005;106: 913–921. doi:10.1182/blood-2004-10-4092
722 723 724	40.	Hardin M, Cho MH, McDonald M-L, Wan E, Lomas DA, Coxson HO, et al. A genome- wide analysis of the response to inhaled $\beta$ 2-agonists in chronic obstructive pulmonary disease. Pharmacogenomics J. 2016;16: 326–335. doi:10.1038/tpj.2015.65

725 726 727	41.	Imboden M, Bouzigon E, Curjuric I, Ramasamy A, Kumar A, Hancock DB, et al. Genome-wide association study of lung function decline in adults with and without asthma. J Allergy Clin Immunol. 2012;129: 1218–1228. doi:10.1016/j.jaci.2012.01.074
728 729 730	42.	Greliche N, Germain M, Lambert J-C, Cohen W, Bertrand M, Dupuis A-M, et al. A genome-wide search for common SNP x SNP interactions on the risk of venous thrombosis. BMC Med Genet. 2013;14: 36. doi:10.1186/1471-2350-14-36
731 732 733	43.	Jackson VE, Latourelle JC, Wain LV, Smith AV, Grove ML, Bartz TM, et al. Meta- analysis of exome array data identifies six novel genetic loci for lung function. Wellcome Open Res. 2018;3: 4. doi:10.12688/wellcomeopenres.12583.3
734 735 736	44.	Germain M, Saut N, Greliche N, Dina C, Lambert J-C, Perret C, et al. Genetics of venous thrombosis: insights from a new genome wide association study. PLoS ONE. 2011;6: e25581. doi:10.1371/journal.pone.0025581
737 738 739	45.	Drobin K, Nilsson P, Schwenk JM. Highly multiplexed antibody suspension bead arrays for plasma protein profiling. Methods Mol Biol. 2013;1023: 137–145. doi:10.1007/978-1-4614-7209-4_8
740 741 742 743	46.	Bruzelius M, Iglesias MJ, Hong M-G, Sanchez-Rivera L, Gyorgy B, Souto JC, et al. PDGFB, a new candidate plasma biomarker for venous thromboembolism: results from the VEREMA affinity proteomics study. Blood. 2016;128: e59–e66. doi:10.1182/blood-2016-05-711846
744 745 746 747	47.	Trégouët D-A, Heath S, Saut N, Biron-Andreani C, Schved J-F, Pernod G, et al. Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. Blood. 2009;113: 5298–5303. doi:10.1182/blood-2008-11-190389
748 749	48.	He H, Bai Y, Garcia EA, Li S. Adaptive synthetic sampling approach for imbalanced learning. IEEE international joint conference on neural networks. 2008; 1322–1328.
750 751 752	49.	Hahnloser RH, Sarpeshkar R, Mahowald MA, Douglas RJ, Seung HS. Digital selection and analogue amplification coexist in a cortex-inspired silicon circuit. Nature. 2000;405: 947–951. doi:10.1038/35016072
753 754 755 756	50.	Bridle JS. Probabilistic Interpretation of Feedforward Classification Network Outputs, with Relationships to Statistical Pattern Recognition. In: Soulié FF, Hérault J (eds) Neurocomputing NATO ASI Series (Series F: Computer and Systems Sciences), vol 68 Springer, Berlin, Heidelberg. 1990. doi:doi.org/10.1007/978-3-642-76153-9_28
757 758	51.	Hinton GE, Dayan P, Frey BJ, Neal RM. The "wake-sleep" algorithm for unsupervised neural networks. Science. 1995;268: 1158–1161. doi:10.1126/science.7761831
759 760	52.	Curry HB. The method of steepest descent for non-linear minimization problems. Quart Appl Math. 1944;2: 258–261.
761 762	53.	Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22: 719–748.

763 764	54.	Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25: 1754–1760. doi:10.1093/bioinformatics/btp324
765 766 767	55.	Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38: e164. doi:10.1093/nar/gkq603
768 769 770	56.	Desch KC, Ozel AB, Halvorsen M, Jacobi PM, Golden K, Underwood M, et al. Whole- exome sequencing identifies rare variants in STAB2 associated with venous thromboembolic disease. Blood. 2020;136: 533–541. doi:10.1182/blood.2019004161
771 772 773	57.	Lindstrom S, Wang L, Smith EN, Gordon W, van Hylckama Vlieg A, de Andrade M, et al. Genomic and Transcriptomic Association Studies Identify 16 Novel Susceptibility Loci for Venous Thromboembolism. Blood. 2019. doi:10.1182/blood.2019000435
774 775 776	58.	Trégouët D-A, Morange P-E. What is currently known about the genetics of venous thromboembolism at the dawn of next generation sequencing technologies. Br J Haematol. 2018;180: 335–345. doi:10.1111/bjh.15004
777 778 779	59.	Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46: 310–315. doi:10.1038/ng.2892
780		
781 782	Sup	porting information captions
782 783 784 785	Sup asso	<b>plementary Figure 1</b> Manhattan plot describing the results of the genome wide ciation study on the LIME predictor
786 786 787 788	<b>Sup</b> MAH	<b>plementary Table</b> 1 List of biological phenotypes that have been measured in RTHA patients
789 790 791	<b>Sup</b> pati	<b>plementary Table 2</b> List of Human Protein Atlas antibodies measured in MARTHA ents
792 793 794	<b>Sup</b> avai	<b>plementary Table 3</b> Correlation between LIME PE predictor and biological traits lable in MARTHA participants used for building the ANN
795 796 797	Sup GW2	<b>plementary Table 4</b> Main statistical associations ( $p < 1 \ge 10^{-5}$ ) observed in the AS on LIME predictor
798 799	Sup sequ	<b>plementary Table 5</b> Rare coding variants identified by whole genome uencing in individual 11.

800





Class PE

# Features







ANN framework

Integration of genetics data